Program Overview

The ASHP-accredited PGY-2 Oncology Pharmacy Residency Program was established in 2007 and was quickly recognized by both physicians and the department as an integral asset to Roswell Park. The residency program provides the opportunities to obtain advanced knowledge and expertise in providing pharmaceutical care to hematology/oncology patients from an interdisciplinary approach with a wide range of health care providers in both inpatient and outpatient settings.

Over the course of 12 months, the resident will gain experience in the management of various solid and hematologic malignancies, become familiar with investigational cancer treatments and become competent recognizing and managing cancer and treatment-related complications.

Purpose Statement

PGY2 pharmacy residency training builds upon the foundations of pharmacy practice established during Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency experience. The purpose of the Roswell Park Comprehensive Cancer Center’s PGY-2 oncology pharmacy residency is to prepare pharmacist clinicians for board certification in oncology pharmacy, advanced patient care positions, or academic positions.


Duration: 12 month
Positions: 4*
       NMS Code 603660 – Roswell Park Track (3 positions)
       NMS Code 603690 – Roswell Park - UB Track (1 position)
Application Deadline: January 6
Estimated Starting Date: First week of July
Approximate Stipend: $53,000
Interview Required: Yes
Curriculum Vitae Required: Yes
Letter of Intent Required: Yes
Letters of Recommendation: 3

The Department of Pharmacy currently employs 20 clinical pharmacy generalists, 17 clinical pharmacy specialists, 6 investigational drug and research pharmacists, 20 pharmacy technicians, 9 pharmacy interns, 4 pharmacy residents and 10 pharmacy administrators.

Contact Information

Eugene Przespolewski, PharmD
Clinical Pharmacist Specialist
Residency Program Director